- Home
- SENEA vs SVRA Comparison
SENEA vs SVRA Comparison
Compare SENEA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | SVRA |
|---|---|---|
| Founded | 1949 | 2007 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 1.1B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | SENEA | SVRA |
|---|---|---|
| Price | $144.78 | $4.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 115.9K | ★ 1.3M |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.99 | $1.98 |
| 52 Week High | $167.52 | $7.01 |
Technical Indicators
Market Signals| Indicator | SENEA | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 43.97 |
| Support Level | $134.17 | $4.78 |
| Resistance Level | $149.14 | $5.43 |
| Average True Range (ATR) | 6.26 | 0.25 |
| MACD | 0.37 | 0.00 |
| Stochastic Oscillator | 66.65 | 38.73 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).